Abstract
This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent MMP inhibitors.
Keywords: MMP-2, MMP-3, MMP-13, rheumatoid arthritis, osteoarthritis, cancer, docking, and zinc binding group.
Current Pharmaceutical Design
Title:Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Volume: 19 Issue: 26
Author(s): Haizhen A. Zhong, Jack Arbiser and J. Phillip Bowen
Affiliation:
Keywords: MMP-2, MMP-3, MMP-13, rheumatoid arthritis, osteoarthritis, cancer, docking, and zinc binding group.
Abstract: This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent MMP inhibitors.
Export Options
About this article
Cite this article as:
Zhong A. Haizhen, Arbiser Jack and Bowen Phillip J., Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors, Current Pharmaceutical Design 2013; 19 (26) . https://dx.doi.org/10.2174/1381612811319260004
DOI https://dx.doi.org/10.2174/1381612811319260004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Sesquiterpenoids as Cytotoxic Anticancer Agents
Mini-Reviews in Medicinal Chemistry Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review
Current Drug Metabolism Prescription Patterns and Compliance with Antimicrobial Stewardship Team Recommendations Among Physicians in a Private Hospital in United Arab Emirates
New Emirates Medical Journal ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential
Protein & Peptide Letters Medicinal Plant <i>Centipeda Minima</i>: A Resource of Bioactive Compounds
Mini-Reviews in Medicinal Chemistry Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Latest Advances in Breast Sonography
Recent Patents on Medical Imaging Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Tissue Transglutaminase Expression During Neural Differentiation of Human Mesenchymal Stem Cells
CNS & Neurological Disorders - Drug Targets Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Current Molecular Medicine Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer
Current Enzyme Inhibition Biological Evaluation and Molecular Modeling of 3,4-dihydropyrimidine- 2(1H)-one Derivatives as Cytotoxic Agents on Breast Cancer In Vitro
Letters in Drug Design & Discovery Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology The Epigenomic Viewpoint on Cellular Differentiation of Myeloid Progenitor Cells as it Pertains to Leukemogenesis
Current Genomics Wnt Signaling and Cell-Matrix Adhesion
Current Molecular Medicine Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued)